Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while decreasing side effect ...

Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while decreasing side effect prevalence and improving lean mass preservation and ...

The European Union has a plan for dealing with increasing cyberattacks against hospitals in its member countries.

One contented customer unveiled their reasoning behind their weight loss, saying ... searching for unique health and fitness resources, Noom offers an approach that concentrates on behavioural ...

Reverse Health has created a 12-week programme specifically for women over 40 who are struggling to lose weight ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...